Valneva (NASDAQ:VALN) Shares Gap Down - What's Next?

Key Points

• Valneva shares opened at $10.50, down from a previous close of $11.02, and last traded at $10.75.
• Analysts have varied opinions on Valneva, with Guggenheim lowering their price target from $14.00 to $13.00 while HC Wainwright maintains a target of $18.00 and a "buy" rating.
• Valneva reported revenue of $54.84 million in their latest quarter, surpassing expectations and marking a notable performance against a backdrop of a negative return on equity of 34.78%.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $11.02, but opened at $10.50. Valneva shares last traded at $10.75, with a volume of 13,487 shares.

Analysts Set New Price Targets

A number of analysts have recently issued reports on VALN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Valneva in a research note on Saturday, September 27th. Guggenheim reduced their price target on shares of Valneva from $14.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday, September 8th. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Valneva in a research report on Monday, August 25th. Wall Street Zen upgraded shares of Valneva to a "hold" rating in a research report on Saturday, September 6th. Finally, Jefferies Financial Group set a $14.00 price target on shares of Valneva and gave the company a "buy" rating in a research note on Monday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.00.

Valneva Trading Down 3.1%

The firm has a market capitalization of $917.30 million, a PE ratio of -10.89 and a beta of 1.86. The firm's fifty day moving average is $9.59 and its two-hundred day moving average is $7.52. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. The business had revenue of $54.84 million for the quarter, compared to analysts' expectations of $46.28 million. On average, equities analysts predict that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marex Group plc purchased a new position in Valneva in the second quarter valued at about $64,000. GAMMA Investing LLC purchased a new position in Valneva in the first quarter valued at about $94,000. Finally, Frazier Life Sciences Management L.P. purchased a new position in Valneva in the second quarter valued at about $8,240,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.